TOP NEWS: AstraZeneca hails survival rates of breast cancer drugs

(Alliance News) - AstraZeneca PLC on Wednesday said its breast cancer drugs capivasertib and ...

Alliance News 26 October, 2022 | 8:36AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Wednesday said its breast cancer drugs capivasertib and camizestrant significantly improved progression-free survival in a phase 3 and 2 trial respectively.

The Cambridge-based pharmaceutical company said capivasertib in combination with hormone therapy drug faslodex, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo in patients with advanced or metastatic breast cancer. The trial met both primary endpoints.

The trial was focused on advanced HR-positive breast cancer.

Susan Galbraith, executive vice president of Oncology research & development at Astra, said the data was "exciting" and shows capivasertib could become a "new first-in-class treatment option".

Meanwhile, camizestrant in a phase 2 trial, showed improved progression free survival rate on people with ER-positive breast cancer. Patients treated with camizestrant had a "significantly improved" survival rate compared to those treated with faslodex.

The results from the trial "underscore the potential for camizestrant to achieve this goal in patients with ER-driven breast cancer and we look forward to advancing our comprehensive Phase 3 clinical programme for camizestrant," said Galbraith.

AstraZeneca shares were 2.4% higher at 9,991.00 pence each in London on Wednesday morning.

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 12,318.00 GBX -0.42

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures